具有脑保护作用的化合物W026B的蛋白质组学研究和靶点发现

doi:10.5246/jcps.2019.06.037

中国药学(英文版) ›› 2019, Vol. 28 ›› Issue (6): 381-392.DOI: 10.5246/jcps.2019.06.037

具有脑保护作用的化合物W026B的蛋白质组学研究和靶点发现

赵思育¹, 刘晓岩^1*, 朱元军¹, 刘晔², 王银叶^1*

1. 北京大学医学部药学院分子与细胞药理学系, 北京 100191
2. 北京红惠新医药科技有限公司, 北京 102600

收稿日期:2019-04-02 修回日期:2019-04-29 出版日期:2019-06-30 发布日期:2019-05-18
通讯作者: Tel.: +86-010-82802652, E-mail: wangyinye@bjmu.edu.cn; liuyan@bjmu.edu.cn
基金资助:
National Natural Science Foundation of China (Grant No. 81503060, 81573333).

The proteomic study and the target discovery of W026B, a new compound with brain protective effect

Siyu Zhao¹, Xiaoyan Liu^1*, Yuanjun Zhu¹, Ye Liu², Yinye Wang^1*

1. Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
2. Beijing Honghui New Medical Technology Co.Ltd., Beijing Daxing Biological Medicine Industry Base, Beijing 102600, China

Received:2019-04-02 Revised:2019-04-29 Online:2019-06-30 Published:2019-05-18
Contact: Tel.: +86-010-82802652, E-mail: wangyinye@bjmu.edu.cn; liuyan@bjmu.edu.cn
Supported by:
National Natural Science Foundation of China (Grant No. 81503060, 81573333).

摘要/Abstract

摘要：

W026B是一种对小鼠脑缺血再灌注(I-R)损伤具有保护作用的新化合物, 但其具体的作用机制尚不明确。本研究应用蛋白质组学观察了W026B在I-R损伤脑组织中对蛋白表达的影响, 并试图揭示其潜在的靶点。通过蛋白质组学共检测到4852种蛋白, 在脑I-R模型组和W026B治疗组中发现了42种发生显著变化的蛋白, 这些蛋白大多与免疫炎症、代谢、神经保护以及细胞增殖和细胞结构有关。经Western blotting验证, 在五种候选蛋白中有三种蛋白表现出与蛋白质组学检测结果一致的改变。我们选择RGS17作为进一步研究的对象, 利用siRNA RGS17敲低RGS17蛋白后加重了脑损伤, 并抵消了W026B的保护作用。W026B可与RGS17结合(K_D: 6.04×10^–⁶ mol/L)。RGS17的下调加重了I型代谢型谷氨酸受体激动剂(I型mGluRs)诱导的Neuro-2a细胞损伤, 并抵消了W026B的保护作用。综上所述, W026B通过影响多种蛋白保护大脑免受I-R损伤, RGS17可能是W026B的靶点之一, 也是潜在的脑I-R损伤治疗靶点。受W026B影响的RGS17调节的G蛋白上游受体可能是I型mGluRs。本研究为W026B的进一步研发和潜在的临床应用提供了有益的证据。

关键词: 脑缺血, 再灌注损伤, 蛋白质组学, 靶点发现, W026B

Abstract:

W026B is a new compound that has a protective effect on cerebral ischemia reperfusion (I-R) injury in mice, while its specific mechanism is still unknown. In this study, proteomics was used to observe the effect of W026B on protein expression in brain I-R tissue, and to reveal its potential target. A total of 42 significantly altered proteins were identified in both brain I-R model and W026B treatment from 4852 proteins detected by proteomics, and most of these proteins were related to immunity and inflammation, metabolism, neuroprotection as well as cell proliferation and cell structure. Western blotting analysis showed that three out of five selected proteins showed consistent alteration with the proteomics. Regulator of G protein signaling 17 (RGS17) was selected for further study, and its knockdown by siRNA RGS17 aggravated brain injury and abolished the protective effect of W026B. W026B could bind with RGS17 (K_D: 6.04×10^–⁶ mol/L). The knockdown of RGS17 aggravated Neuro-2a cell damage induced by group I metabotropic glutamate receptors (mGluRs) agonist, and abolished the protective effect of W026B. In conclusion, W026B protected brain against I-R injury by affecting diverse proteins. RGS17 might be one of its targets and a potential therapeutic target of brain I-R injury. The upstream receptor of G protein, which was regulated by RGS17 and affected by W026B, might be group I mGluRs. This study provided useful evidence for the further R&D and the potential clinical application of W026B.

Key words: Brain ischemia, Reperfusion injury, Proteomics, Target discovery, W026B

中图分类号:

R965

Supporting:

赵思育, 刘晓岩, 朱元军, 刘晔, 王银叶. 具有脑保护作用的化合物W026B的蛋白质组学研究和靶点发现[J]. 中国药学(英文版), 2019, 28(6): 381-392.

Siyu Zhao, Xiaoyan Liu, Yuanjun Zhu, Ye Liu, Yinye Wang. The proteomic study and the target discovery of W026B, a new compound with brain protective effect[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(6): 381-392.

参考文献

[1] Moskowitz, M.A.; Lo, E.H.; Iadecola, C. The science of stroke: mechanisms in search of treatments. Neuron. 2010, 67, 181-198.

[2] Wang, Y.; Shen, J.G.; Wang, X.M.; Fu, D.L.; Chen, C.Y.; Lu, L.Y.; Lu, L.; Xie, C.L.; Fang, J.Q.; Zheng, G.Q. Scalp acupuncture for acute ischemic stroke: a meta-analysis of randomized controlled trials. Evid. Based. Complement. Alternat. Med. 2012, 2012, 480950.

[3] Röther, J.; Ford, G.A.; Thijs, V.N. Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. Cerebrovasc. Dis. 2013, 35, 313-319.

[4] Goyal, M.; Menon, B.K.; van Zwam, W.H.; Dippel, D.W.J.; Mitchell, P.J.; Demchuk, A.M.; Dávalos, A.; Majoie, C.B.L.M.; van der Lugt, A.; de Miquel, M.A.; Donnan, G.A.; Roos, Y.B.W.E.M.; Bonafe, A.; Jahan, R.; Diener, H.C.; van den Berg, L.A.; Levy, E.I.; Berkhemer, O.A.; Pereira, V.M.; Rempel, J.; Millán, M.; Davis, S.M.; Roy, D.; Thornton, J.; Román, L.S.; Ribó, M.; Beumer, D.; Stouch, B.; Brown, S.; Campbell, B.C.V.; van Oostenbrugge, R.J.; Saver, J.L.; Hill, M.D.; Jovin, T.G. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016, 387, 1723-1731.

[5] Balami, J.S.; Chen, R.L.; Sutherland, B.A.; Buchan, A.M. Thrombolytic agents for acute ischaemic stroke treatment: the past, present and future. CNS Neurol. Disord. Drug Targets. 2013, 12, 145-154.

[6] Balami, J.S.; Sutherland, B.A.; Edmunds, L.D.; Grunwald, I.Q.; Neuhaus, A.A.; Hadley, G.; Karbalai, H.; Metcalf, K.A.; DeLuca, G.C.; Buchan, A.M. A systematic review and meta-analysis of randomized controlled trials of endovascular thrombectomy compared with best medical treatment for acute ischemic stroke. Int. J. Stroke. 2015, 10, 1168-1178.

[7] Zhu, Y.J.; Gao, Y.Q.; Zheng, D.P.; Shui, M.Y.; Yu, K.; Liu, X.Y.; Lin, Y.; Su, L.; Yang, W.X.; Wang, Y.Y. Design and evaluation of EphrinA1 mutants with cerebral protective effect. Sci. Rep. 2017, 7, 1881.

[8] Bu, Q.X.; Liu, X.Y.; Zhu, Y.J.; Liu, Y.; Wang, Y.Y. W007B protects brain against ischemia-reperfusion injury in rats through inhibiting inflammation, apoptosis and autophagy. Brain Res. 2014, 1558, 100-108.

[9] Wang, Y.; Liu, Y.; Zhang, P.; Tong, W.; Cai, Y. Magnolol derivatives, honokiol derivatives and their preparation method and application. China, 2013.

[10] Ye, Z. A new compound W026B alleviates ischemic brain injury through inhibiting the production of inflammatory cytokines in pMCAO and tMCAO, and enhances the beneficial effect of tPA. J. Chin. Pharm. Sci. 2018, 27, 675-685.

[11] Zhang, Z.J.; Zhang, G.X.; Sun, Y.W.; Szeto, S.S.W.; Law, H.C.H.; Quan, Q.; Li, G.H.; Yu, P.; Sho, E.; Siu, M.K.W.; Lee, S.M.Y.; Chu, I.K.; Wang, Y.Q. Tetramethylpyrazine nitrone, a multifunctional neuro-protective agent for ischemic stroke therapy. Sci. Rep. 2016, 6, 37148.

[12] Llombart, V.; Trejo, S.A.; Bronsoms, S.; Morancho, A.; Ma, F.F.; Faura, J.; García-Berrocoso, T.; Simats, A.; Rosell, A.; Canals, F.; Hernández-Guillamón, M.; Montaner, J. Profiling and identification of new proteins involved in brain ischemia using MALDI-imaging-mass-spectrometry. J. Proteomics. 2017, 152, 243-253.

[13] Shah, F.A.; Park, D.J.; Koh, P.O. Identification of proteins differentially expressed by quercetin treatment in a middle cerebral artery occlusion model: A proteomics approach. Neurochem. Res. 2018, 43, 1608-1623.

[14] Shui, M.Y.; Liu, X.Y.; Zhu, Y.J.; Wang, Y.Y. Exogenous hydrogen sulfide attenuates cerebral ischemia-reperfusion injury by inhibiting autophagy in mice. Can. J. Physiol. Pharmacol. 2016, 94, 1187-1192.

[15] Zhang, G.C.; Chen, L.; Yang, L.L.; Hua, X.D.; Zhou, B.Q.; Miao, Z.G.; Li, J.Z.; Hu, H.; Namaka, M.; Kong, J.M.; Xu, X.S. Combined use of spatial restraint stress and middle cerebral artery occlusion is a novel model of post-stroke depression in mice. Sci. Rep. 2015, 5, 16751.

[16] Wiśniewski, J.R.; Zougman, A.; Nagaraj, N.; Mann, M. Universal sample preparation method for proteome analysis. Nat. Methods 2009, 6, 359-362.

[17] Hu, Z.Y.; Bian, X.L.; Liu, X.Y.; Zhu, Y.J.; Zhang, X.Y.; Chen, S.Z.; Wang, K.W.; Wang, Y.Y. Honokiol protects brain against ischemia-reperfusion injury in rats through disrupting PSD95-nNOS interaction. Brain Res. 2013, 1491, 204-212.

[18] Zhang, H.P.; Wang, F.; Kranzler, H.R.; Anton, R.F.; Gelernter, J. Variation in regulator of G-protein signaling 17 gene (RGS17) is associated with multiple substance dependence diagnoses. Behav. Brain Funct. 2012, 8, 23.

[19] Soundararajan, M.; Willard, F.S.; Kimple, A.J.; Turnbull, A.P.; Ball, L.J.; Schoch, G.A.; Gileadi, C.; Fedorov, O.Y.; Dowler, E.F.; Higman, V.A.; Hutsell, S.Q.; Sundström, M.; Doyle, D.A.; Siderovski, D.P. Structural diversity in the RGS domain and its interaction with heterotrimeric G protein alpha-subunits. Proc. Natl. Acad. Sci. USA. 2008, 105, 6457-6462.

[20] Kimple, A.J.; Bosch, D.E.; Giguère, P.M.; Siderovski, D.P. Regulators of G-protein signaling and their Gα substrates: promises and challenges in their use as drug discovery targets. Pharmacol. Rev. 2011, 63, 728-749.

[21] Roman, D.L.; Traynor, J.R. Regulators of G protein signaling (RGS) proteins as drug targets: modulating G-protein-coupled receptor (GPCR) signal transduction. J. Med. Chem. 2011, 54, 7433-7440.

[22] Larminie, C.; Murdock, P.; Walhin, J.P.; Duckworth, M.; Blumer, K.J.; Scheideler, M.A.; Garnier, M. Selective expression of regulators of G-protein signaling (RGS) in the human central nervous system. Brain Res. Mol. Brain Res. 2004, 122, 24-34.

[23] Garzón, J.; Rodríguez-Muñoz, M.; Vicente-Sánchez, A.; Bailón, C.; Martínez-Murillo, R.; Sánchez-Blázquez, P. RGSZ2 binds to the neural nitric oxide synthase PDZ domain to regulate mu-opioid receptor-mediated potentiation of the N-methyl-D-aspartate receptor-calmodulin-dependent protein kinase II pathway. Antioxid. Redox Signal. 2011, 15, 873-887.

[24] Mao, H.; Zhao, Q.S.; Daigle, M.; Ghahremani, M.H.; Chidiac, P.; Albert, P.R. RGS17/RGSZ2, a novel regulator of Gi/o, Gz, and Gq signaling. J. Biol. Chem. 2004, 279, 26314-26322.

[25] Lafourcade, C.A.; Zhang, L.H.; Alger, B.E. Novel mGluR- and CB1R-independent suppression of GABA release caused by a contaminant of the group I metabotropic glutamate receptor agonist, DHPG. PLoS One. 2009, 4, e6122.

[26] Kohara, A.; Takahashi, M.; Yatsugi, S.; Tamura, S.; Shitaka, Y.; Hayashibe, S.; Kawabata, S.; Okada, M. Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res. 2008, 1191, 168-179.

[27] Rao, A.M.; Hatcher, J.F.; Dempsey, R.J. Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci. Lett. 2000, 293, 1-4.

[28] Liu, B.; Dong, Q.; Zhang, S.Y.; Su, D.Y.; Yang, Z.C.; Lv, M.; Zhang, S.Y. MGluR1, 5 activation protects cortical astrocytes and GABAergic neurons from ischemia-induced impairment. Neurosci. Res. 2013, 75, 160-166.

[29] Pai, M.Y.; Lomenick, B.; Hwang, H.; Schiestl, R.; McBride, W.; Loo, J.A.; Huang, J. Drug affinity responsive target stability (DARTS) for small-molecule target identification. Methods Mol. Biol. 2015, 1263, 287-298.

[30] Lomenick, B.; Jung, G.; Wohlschlegel, J.A.; Huang, J. Target identification using drug affinity responsive target stability (DARTS). Curr. Protoc. Chem. Biol. 2011, 3, 163-180.

具有脑保护作用的化合物W026B的蛋白质组学研究和靶点发现

The proteomic study and the target discovery of W026B, a new compound with brain protective effect

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王番, 李锐莉, 王文军, 周晓燕, 刘美佑, 赵瑾怡, 文爱东, 王婧雯, 贾艳艳. α-乳香酸通过抑制TLR4介导的炎症通路改善急性肾损伤[J]. 中国药学(英文版), 2023, 32(7): 539-550.
[2]	杨滢霖, 张姗姗, 刘漫, 刘冬妮, 王月华, 杜冠华. 小续命汤抗缺血性脑卒中网络药理学分析及其抗炎和神经血管保护机制的体内验证[J]. 中国药学(英文版), 2022, 31(5): 343-359.
[3]	王子翼, 刘晓岩, 朱元军, 刘晔, 张平平, 王银叶. W026B对大鼠全脑缺血再灌注损伤的保护作用[J]. 中国药学(英文版), 2022, 31(2): 108-116.
[4]	商燕, 蔺晓源, 张田田, 谢丽华, 胡国恒. 基于网络药理学和分子对接探讨益气活血方抗脑缺血机制研究[J]. 中国药学(英文版), 2022, 31(2): 117-133.
[5]	杨滢霖, 张姗姗, 刘漫, 王月华, 杜冠华. 小续命汤提取物改善血栓性局灶性脑缺血大鼠脑损伤及利用蛋白质组学探讨其可能治疗靶点[J]. 中国药学(英文版), 2021, 30(6): 468-483.
[6]	洪倩, 王增慧, 杨阳, 高璐, 闫兆. 银杏二萜内酯葡胺注射液通过调控炎症和凋亡信号通路减轻OGD/R诱导的细胞损伤[J]. 中国药学(英文版), 2020, 29(7): 455-469.
[7]	王圣鑫, 闫向丽, 郑昊圳, 余健烨, 余爱明, 沈晓, 王利胜. 微透析技术结合液质联用的不同剂量黄芪的补阳还五汤在脑缺血损伤大鼠脑药动学研究[J]. 中国药学(英文版), 2020, 29(2): 90-101.
[8]	高克祥, 刘晓岩, 朱元军, 刘晔, 王银叶. B55γ蛋白对t-MCAO模型小鼠中W026B神经保护作用的影响[J]. 中国药学(英文版), 2020, 29(10): 711-718.
[9]	宋宇靖, 赵旭阳, 陈倩, 宋艳, 雷婉玉, 尹玉新, 马维宁, 黄卓. 应用蛋白质组学方法评估抗癫痫药物卡马西平对颞叶癫痫患者脑组织蛋白质组的影响[J]. 中国药学(英文版), 2020, 29(1): 13-28.
[10]	于快, 李茹一, 朱元军, 刘晓岩, 王银叶. 针对脑缺血再灌注损伤设计的双功能蛋白的脑保护作用优于单功能蛋白[J]. 中国药学(英文版), 2019, 28(11): 760-769.
[11]	何鹿玲, 龚琴, 余煊, 王木兰, 翁莎莎, 雷帆, 高红伟, 罗颖颖, 冯育林, 杨世林, 李俊, 杜力军. 腺嘌呤所致大鼠肾损伤的蛋白质组变化及其白头翁皂苷B4的调节作用[J]. 中国药学(英文版), 2019, 28(1): 10-20.
[12]	庞雨浓, 梁英文, 王玉刚, 雷帆, 袁梽漪, 邢东明, 李俊, 杜力军. 小檗碱通过调节PPARγ启动子甲基化对缺血再灌注脑损伤的作用[J]. 中国药学(英文版), 2018, 27(3): 170-182.
[13]	张烨, 郑丹萍, 水梦洋, 刘晔, 刘晓岩, 王银叶. 新化合物W026B通过抑制炎性细胞因子的产生减轻缺血性脑损伤, 与tPA合用作用增强[J]. 中国药学(英文版), 2018, 27(10): 675-685.
[14]	沈婉丽, 于飞, 徐璐, 陈聪, 曹旖旎, 刘姝, 韩南银, 王超, 祁荣. 丹参酮IIA衍生物对大鼠心肌缺血再灌注损伤的保护作用[J]. 中国药学(英文版), 2018, 27(1): 1-13.
[15]	尹成, 王杰, 徐沛, 颜丙春. 薯蓣皂苷通过降低胶质细胞活化及维持SOD水平减轻脑卒中小鼠的神经损伤[J]. 中国药学(英文版), 2017, 26(9): 684-691.